CVS Health Corp. (CVS) Stock Competitors & Peer Comparison
See (CVS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CVS | $107.61 | +0.13% | 137.3B | 15.22 | $7.07 | +2.48% |
| UNH | $421.55 | -1.07% | 383.1B | 25.82 | $16.34 | +2.12% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.42% |
| ELV | $382.23 | +2.44% | 82.9B | 13.01 | $29.39 | +1.79% |
| CI | $283.94 | +0.88% | 75.1B | 9.19 | $30.90 | +2.16% |
| HUM | $398.20 | -0.45% | 47.8B | 25.11 | $15.86 | +0.89% |
| CNC | $65.84 | -0.90% | 32.5B | 26.13 | $2.52 | N/A |
| MOH | $229.71 | +1.93% | 12B | 33.18 | $6.92 | N/A |
| OSCR | $29.60 | +1.72% | 7.7B | -50.19 | -$0.59 | N/A |
| ALHC | $21.10 | +2.43% | 4.4B | 234.44 | $0.09 | N/A |
Stock Comparison
CVS vs UNH Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, UNH has a market cap of 383.1B. Regarding current trading prices, CVS is priced at $107.61, while UNH trades at $421.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas UNH's P/E ratio is 25.82. In terms of profitability, CVS's ROE is +0.04%, compared to UNH's ROE of +0.12%. Regarding short-term risk, CVS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check UNH's competition here
CVS vs ANTM Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CVS is priced at $107.61, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CVS's ROE is +0.04%, compared to ANTM's ROE of +0.11%. Regarding short-term risk, CVS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ANTM's competition here
CVS vs ELV Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, ELV has a market cap of 82.9B. Regarding current trading prices, CVS is priced at $107.61, while ELV trades at $382.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas ELV's P/E ratio is 13.01. In terms of profitability, CVS's ROE is +0.04%, compared to ELV's ROE of +0.11%. Regarding short-term risk, CVS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ELV's competition here
CVS vs CI Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, CI has a market cap of 75.1B. Regarding current trading prices, CVS is priced at $107.61, while CI trades at $283.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas CI's P/E ratio is 9.19. In terms of profitability, CVS's ROE is +0.04%, compared to CI's ROE of +0.15%. Regarding short-term risk, CVS is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check CI's competition here
CVS vs HUM Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, HUM has a market cap of 47.8B. Regarding current trading prices, CVS is priced at $107.61, while HUM trades at $398.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas HUM's P/E ratio is 25.11. In terms of profitability, CVS's ROE is +0.04%, compared to HUM's ROE of +0.06%. Regarding short-term risk, CVS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check HUM's competition here
CVS vs CNC Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, CNC has a market cap of 32.5B. Regarding current trading prices, CVS is priced at $107.61, while CNC trades at $65.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas CNC's P/E ratio is 26.13. In terms of profitability, CVS's ROE is +0.04%, compared to CNC's ROE of -0.29%. Regarding short-term risk, CVS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CNC's competition here
CVS vs MOH Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, MOH has a market cap of 12B. Regarding current trading prices, CVS is priced at $107.61, while MOH trades at $229.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas MOH's P/E ratio is 33.18. In terms of profitability, CVS's ROE is +0.04%, compared to MOH's ROE of +0.04%. Regarding short-term risk, CVS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check MOH's competition here
CVS vs OSCR Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, OSCR has a market cap of 7.7B. Regarding current trading prices, CVS is priced at $107.61, while OSCR trades at $29.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas OSCR's P/E ratio is -50.19. In terms of profitability, CVS's ROE is +0.04%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, CVS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check OSCR's competition here
CVS vs ALHC Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, ALHC has a market cap of 4.4B. Regarding current trading prices, CVS is priced at $107.61, while ALHC trades at $21.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas ALHC's P/E ratio is 234.44. In terms of profitability, CVS's ROE is +0.04%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, CVS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ALHC's competition here
CVS vs CLOV Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, CLOV has a market cap of 2.3B. Regarding current trading prices, CVS is priced at $107.61, while CLOV trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas CLOV's P/E ratio is -37.50. In terms of profitability, CVS's ROE is +0.04%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, CVS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CLOV's competition here
CVS vs BHG Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CVS is priced at $107.61, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas BHG's P/E ratio is -0.12. In terms of profitability, CVS's ROE is +0.04%, compared to BHG's ROE of +0.04%. Regarding short-term risk, CVS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check BHG's competition here
CVS vs CABR Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, CABR has a market cap of 20.2M. Regarding current trading prices, CVS is priced at $107.61, while CABR trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas CABR's P/E ratio is -2.45. In terms of profitability, CVS's ROE is +0.04%, compared to CABR's ROE of -3.28%. Regarding short-term risk, CVS is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CABR's competition here
CVS vs AET Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, AET has a market cap of 0. Regarding current trading prices, CVS is priced at $107.61, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas AET's P/E ratio is 9.57. In terms of profitability, CVS's ROE is +0.04%, compared to AET's ROE of +0.11%. Regarding short-term risk, CVS is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check AET's competition here
CVS vs GTS Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CVS is priced at $107.61, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas GTS's P/E ratio is 10.41. In terms of profitability, CVS's ROE is +0.04%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CVS is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check GTS's competition here
CVS vs MGLN Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CVS is priced at $107.61, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CVS's ROE is +0.04%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CVS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check MGLN's competition here
CVS vs UAM Comparison July 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 137.3B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CVS is priced at $107.61, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 15.22, whereas UAM's P/E ratio is 1.01. In terms of profitability, CVS's ROE is +0.04%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CVS is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check UAM's competition here